TY - JOUR
T1 - Preeclampsia and coronary plaque erosion
T2 - Manifestations of endothelial dysfunction resulting in cardiovascular events in women
AU - de Jager, Saskia C.A.
AU - Meeuwsen, John A.L.
AU - van Pijpen, Freeke M.
AU - Zoet, Gerbrand A.
AU - Barendrecht, Arjan D.
AU - Franx, Arie
AU - Pasterkamp, Gerard
AU - van Rijn, Bas B.
AU - Goumans, Marie José
AU - den Ruijter, Hester M.
N1 - Funding Information:
This work was supported by the Dutch Heart Foundation ( 2013T084 , Queen of Hearts program and 2013 T083 , CREw-IMAGO ).
Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017/12/5
Y1 - 2017/12/5
N2 - Atherosclerosis is the major underlying pathology of cardiovascular disease (CVD). The risk for CVD is increased in women with a history of preeclampsia. Multiple studies have indicated that accelerated atherosclerosis underlies this increased CVD risk. Furthermore, it has been suggested that endothelial dysfunction and inflammation play an important role in the increased CVD risk of women with preeclampsia. Rupture or erosion of atherosclerotic plaques can induce the formation of thrombi that underlie the onset of acute clinical CVD such as myocardial infarction and stroke. In relatively young women, cardiovascular events are mainly due to plaque erosions. Eroded plaques have a distinct morphology compared to ruptured plaques, but have been understudied as a substrate for CVD. The currently available evidence points towards lesions with features of stability such as high collagen content and smooth muscle cells and with distinct mechanisms that further promote the pro-thrombotic environment such as Toll Like Receptor (TLR) signaling and endothelial apoptosis. These suggested mechanisms, that point to endothelial dysfunction and intimal thickening, may also play a role in preeclampsia. Pregnancy is considered a stress test for the cardiovascular system with preeclampsia as an additional pathological substrate for earlier manifestation of vascular disease. This review provides a summary of the possible common mechanisms involved in preeclampsia and accelerated atherosclerosis in young females and highlights plaque erosion as a likely substrate for CVD events in women with a history of preeclampsia.
AB - Atherosclerosis is the major underlying pathology of cardiovascular disease (CVD). The risk for CVD is increased in women with a history of preeclampsia. Multiple studies have indicated that accelerated atherosclerosis underlies this increased CVD risk. Furthermore, it has been suggested that endothelial dysfunction and inflammation play an important role in the increased CVD risk of women with preeclampsia. Rupture or erosion of atherosclerotic plaques can induce the formation of thrombi that underlie the onset of acute clinical CVD such as myocardial infarction and stroke. In relatively young women, cardiovascular events are mainly due to plaque erosions. Eroded plaques have a distinct morphology compared to ruptured plaques, but have been understudied as a substrate for CVD. The currently available evidence points towards lesions with features of stability such as high collagen content and smooth muscle cells and with distinct mechanisms that further promote the pro-thrombotic environment such as Toll Like Receptor (TLR) signaling and endothelial apoptosis. These suggested mechanisms, that point to endothelial dysfunction and intimal thickening, may also play a role in preeclampsia. Pregnancy is considered a stress test for the cardiovascular system with preeclampsia as an additional pathological substrate for earlier manifestation of vascular disease. This review provides a summary of the possible common mechanisms involved in preeclampsia and accelerated atherosclerosis in young females and highlights plaque erosion as a likely substrate for CVD events in women with a history of preeclampsia.
KW - Atherosclerosis
KW - Cardiovascular disease
KW - endMT
KW - Endothelial dysfunction
KW - Inflammation
KW - Preeclampsia
UR - http://www.scopus.com/inward/record.url?scp=85029228292&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2017.09.012
DO - 10.1016/j.ejphar.2017.09.012
M3 - Article
C2 - 28899695
SN - 0014-2999
VL - 816
SP - 129
EP - 137
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
ER -